877131-77-6

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-[(4-bromo-2-ethylphenyl)methyl]-
• CAS NO: 877131-77-6
• Molecular Formula: C17H14BrNO2
• Molecular Weight: 344.208
• Mol File: 877131-77-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-[(4-bromo-2-ethylphenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-[(4-bromo-2-ethylphenyl)methyl]-(877131-77-6)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-[(4-bromo-2-ethylphenyl)methyl]-(877131-77-6)

Safety Data

• Hazardous Substances Data: 877131-77-6(Hazardous Substances Data)

Usage

Structure

Derived from isoindole-1,3-dione with a bromine atom and an ethyl group attached to the phenyl ring.

Reactivity

The presence of the bromine atom and the ethyl group can potentially affect the compound's reactivity.

Uses

Medicinal applications and as a chemical intermediate in the synthesis of other compounds for various industrial purposes.

Upstream product

• 136918-14-4 phthalimide 
• 877131-21-0 (4-bromo-2-ethylphenyl)methanol 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 644984-78-1 4-bromo-2-ethylbenzoic acid 
• 877131-22-1 4-bromo-1-(bromomethyl)-2-ethylbenzene 

Downstream Products

• 877131-68-5 4-bromo-2-ethyl-benzylamine 

Relevant articles and documents

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).